B cell-targeted therapy for rheumatoid arthritis: An update on the evidence

Drugs

Volumn 66, Issue 5, 2006, Pages 625-639

  Looney, R John ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GROWTH FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERFERON; INTERLEUKIN 1BETA ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; ANGIONEUROTIC EDEMA; ARTHROPATHY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BACKACHE; BRONCHITIS; BRONCHOSPASM; CARDIOGENIC SHOCK; CD4+ T LYMPHOCYTE; CHILL; CLINICAL TRIAL; CRYOGLOBULINEMIA; DEATH; DERMATOMYOSITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EPIGLOTTITIS; FATIGUE; FEVER; FLUSHING; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOGAMMAGLOBULINEMIA; HYPOXIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LICHENOID ERUPTION; LUNG INFILTRATE; LUNG PRESSURE; MOUTH INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PALLOR; PAPULOVESICULAR RASH; PNEUMONIA; PROGNOSIS; PYELONEPHRITIS; RASH; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SHOCK; SIDE EFFECT; SINUSITIS; STEVENS JOHNSON SYNDROME; SYNOVIOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE;

ANIMALIA;

EID: 33646342760     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666050-00004     Document Type: Review

References (80)

1. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997; 40 (4): 598-609
2. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996; 39 (11): 1781-90
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [see comment]. N Engl J Med 2004; 350 (25): 2572-81
4. Emery P, Fleischmann RM, Filipowicz-Sosnowska A, et al. Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial [abstract 263]. Arthritis Rheum 2005; 52 (Suppl.): S130
5. Cohen SB, M Greenwald, Dougados MR, et al. Efficacy and safety of rituximab in active RA patients who experienced inadequate response to one or more anti-TNFaα therapies (REFLEX Study) [abstract 1830]. Arthritis Rheum 2005; 52 (Suppl.):S677
6. Dorner T, Egerer K, Feist E, et al. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16 (3): 246-53
7. Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973; 16: 265-336
8. O'Neill SK, Shlomchik MJ, Glant TT, et al. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005; 174 (6): 3781-8
9. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis [comment]. N Engl J Med 1997; 337 (3): 195-7
10. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial [see comment]. Lancet 2004; 363 (9410): 675-81
11. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group [see comment]. N Engl J Med 2000; 343 (22): 1594-602
12. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [see comment; published erratum appears in Arthritis Rheum 2003 Mar; 48 (3): 855]. Arthritis Rheum 2003; 48 (1): 35-45
13. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50 (11): 3432-43
14. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes [see comment]. Arthritis Rheum 2002; 46 (6): 1443-50
15. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [see comment; published erratum appears in N Engl J Med 2001 Jan 18; 344 (3): 240]. N Engl J Med 2000; 343 (22): 1586-93
16. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998; 37 (2): 126-30
17. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97 (2): 188-96
18. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167 (8): 4710-8
19. Mathsson L, Lampa J, Mullazehi M, et al. Immune complexes from RA symovial fluids induce Fc(gamma)IIa-dependent and rheumatoid factor correlated production of TNF-alpha-production from peripheral blood mononuclear cells [abstract 159]. Arthritis Rheum 2005; 52 (Suppl.): S271
20. Tedder TF, Streuli M, Schlossman SF, et al. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988; 85 (1): 208-12
21. Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem 1988; 263 (20): 10009-15
22. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15 (9): 450-4
23. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135 (2): 973-9
24. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985; 135 (6): 3795-801
25. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95 (12): 3900-8
26. Anolik JH, Looney RJ, Bottaro A, et al. Down-regulation of CD20 on B cells upon CD40 activation. Eur J Immunol 2003; 33: 2398-409
27. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2): 435-45
28. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90 (6): 2188-95
29. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29 (1 Suppl. 2): 2-9
30. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21 (21): 3940-7
31. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa. Blood 2002; 99: 754-8
32. Anolik JH, Campbell D, Felgar R, et al. The relationship of FcgRIIIa genotype to degree of B cell depletion by rituximab in the treatment of SLE. Arthritis Rheum 2003; 48: 455-9
33. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17 (1): 268-76
34. Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13 (5): 381-90
35. PDR drug information for rituxan for infusion [online]. Available from URL: http://www.drugs.com/PDR/Rituxan_for_ Infusion.html#W10 [Accessed 2006 Jan 19]
36. Brandon S, Kistler P, Jenunet F. Intravenous administration of human gammaglobulin. Vox Sanguis 1962; 7: 157-74
37. Roberton DM, Hosking CS. Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial. Aust Paediatr J 1988; 24 (3): 174-7
38. Lederman HM, Roifman CM, Lavi S, et al. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 1986; 81 (3): 443-6
39. Jardin F, Levesque H, Tilly H. [Auto-immune manifestations in non-Hodgkin's lymphoma]. Rev Med Interne 2005; 26 (7): 557-71
40. Lim SH, Zhang Y, Wang Z, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005; 35 (2): 207-8
41. Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol 2005; 23 (1): 247-8
42. Bermudez A, Marco F, Conde E, et al. Fatal visceral varicellazoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85 (8): 894-5
43. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358 (9292): 1511-3
44. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101 (10): 3857-61
45. Looney RJ, Huggins JL. Use of intravenous IgG (IVIG). Best Pract Res Clin Haematol 2006; 19 (1): 3-25
46. Albert D, Khan S, Stansberry J, et al. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract 112.5]. Arthritis Rheum 2004; 50 (Suppl.): S446
47. Gonzalez-Stawinski GV, Yu PB, Love SD, et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Clin Immunol 2001; 98 (2): 175-9
48. van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100 (6): 2257-9
49. Bearden CM, Agarwal A, Book BK, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005; 5 (1): 50-7
50. Isobe Y, Sugimoto K, Shiraki Y, et al. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004; 77 (4): 370-3
51. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348 (26): 2691-4; discussion 2691-4
52. Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106 (3): 795-802
53. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comment]. Arthritis Rheum 1998; 41 (9): 1552-63
54. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16 (8): 2825-33
55. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50 (8): 2580-9
56. Abrahams VM, Cambridge G, Lydyard PM, et al. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000; 43 (3): 608-16
57. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001; 40 (2): 205-11
58. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion [see comment]. Ann Rheum Dis 2002; 61 (10): 883-8
59. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46 (8): 2029-33
60. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004; 33 (2): 82-6
61. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64 (6): 913-20
62. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48 (8): 2146-54
63. Edwards JC, Leandro MJ, Cambridge G. Repeated B lymphocyte depletion therapy in rheumatoid arthritis [abstract 270]. Arthritis Rheum 2005; 52 Suppl.: S13S
64. Magrini F, Grunert VP, Ebert H, et al. Correlation of serum biochemical markers with response to treatment of rheumatoid arthritis with rituximab [abstract 1461]. Arthritis Rheum 2005; 52 (Suppl.): S550
65. Pavelka K, Emory P, Filipowicz-Sosnowska A, et al. Efficacy and safety following repeated courses of rituximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64 (Suppl. III): 435
66. Fleischmann RM, Emery P, Filipowicz-Sosnowska A, et al. Coadministration of glucocorticoids does not influence efficacy of, but reduces infusion reactions to, rituximab in rheumatoid arthritis: results from the DANCER Study [abstract 263]. Arthritis Rheum 2005; 52 (Suppl.): S130
67. van Vollenhoven R, Schechtman J, Szcepanski L, et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: results from the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) study [abstract 1922]. Arthritis Rheum 2005; 52 (Suppl.): S711
68. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides [see comment]. Arthritis Rheum 2001; 44 (12): 2862-9
69. Harris DP, Goodrich S, Gerth AJ, et al. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 2005; 174 (11): 6781-90
70. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nature Immunol 2002; 3 (10): 944-50
71. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells [see comment]. Nature Immunol 2000; 1 (6): 475-82
72. Amedei A, Romagnani C, Benagiano M, et al. Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia. Eur J Immunol 2001; 31 (6): 1927-34
73. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 2005; 175: 15-20
74. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, et al. Natural antibodies sustain differentiation and maturation of human dendritic cell. Proc Natl Acad Sci U S A 2004; 101: 14210-5
75. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous imumunoglobulin. Blood 2003; 101: 758-65
76. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125 (2): 232-9
77. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167 (2): 1072-80
78. McKay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population [abstract 1920]. Arthritis Rheum 2005; 52 (Suppl.): S710
79. Genovese M, Filipowicz-Sosnowska A, Merrill J, et al. Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF+, TNFaα-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis [abstract 1989]. Arthritis Rheum 2005; 52 (Suppl.): S735
80. Stohl W, Chatham W, Weisman M, et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population [abstract 1160]. Arthritis Rheum 2005; 52 (Suppl.): S444